Kwonjune Justin Seung, M.D.
This page shows the publications co-authored by Kwonjune Seung and Leonid Lecca.
Introducing new and repurposed TB drugs: the endTB experience. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1081-1086.
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2020 07 11; 71(2):415-418.
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J. 2022 01; 59(1).
Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort. Clin Infect Dis. 2022 Jan 13.
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021 01 01; 203(1):111-119.
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666.
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 08 27; 16(1):453.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.